Background and Aims Subcutaneous (SC) vedolizumab presents the opportunity for inflammatory bowel disease (IBD) patients to manage their treatment at home. There is currently no data on the process of transitioning patients established on intravenous (IV) to SC as part of routine clinical care. The aim of this programme is to evaluate the clinical and biochemical outcomes of switching a cohort of IBD patients established on IV vedolizumab to SC 12 weeks following the transition. Methods 178 adult patients were offered the opportunity to transition to SC vedolizumab. Patients who agreed were reviewed prior to switching and at week 12 (W12) after their first SC dose. Evaluation outcomes included disease activity scores, the IBD-Control patient-reported outcome measures (PROMs) and faecal calprotectin (FCP). Reasons for patients declining or accepting transitioning, pharmacokinetics, adverse drug reactions and risk factors for a poor outcome in SARS-CoV-2 infection were also assessed. Results 124 patients agreed to transition, of which 106 patients had been on IV vedolizumab for at least 4 months. There were no statistically significant differences in disease activity scores or IBD-Control PROMs between baseline and W12. A statistically significant increase in FCP was observed (31µg/g vs. 47µg/g; p=0.008), although this was unlikely to be clinically relevant. The most common adverse drug reaction reported was injection site reactions (15%). Based on this cohort of patients, an expected reduction of £572,000 per annum is likely to be achieved. Conclusions Transitioning patients established on IV vedolizumab to SC appears to be safe and effective, with high patient satisfaction and multiple benefits for the health service.
Suicides and suicidal behaviors are very important causes of mortality and morbidity and have become a serious global problem. More than 800,000 people die from suicide every year. Previous researches have established that lipids play an important role in the pathogenesis of suicide. Moreover, lipid levels might be a biological marker of suicide. A lot of researchers have tried to identify biological markers that might be related to depressive disorder, bipolar disorder or schizophrenia and suicidal behavior. It was also important to consider the usefulness of an additional tool for prevention actions. Metabolic deregulation, particularly low total cholesterol and low-density lipoproteins-cholesterol levels may cause higher suicide risk in patients with these psychiatric disorders.
Cel pracyCelem pracy była ocena podaży wybranych witamin i składników mineralnych w całodziennych racjach pokarmowych pacjentów z rozpoznaniem schizofrenii.MetodaBadaniami objęto grupę 62 osób (32 kobiety i 30 mężczyzn w wieku 21-64 lata, średni wiek kobiet wynosił 41,3±11,2 lat, a mężczyzn 36,1±9,7 lat) chorujących na schizofrenię. W ocenie ilościowej sposobu żywienia wykorzystano wywiad 24-godzinny zebrany z 3 dni powszednich i jednego dnia weekendowego.WynikiW przeprowadzonych badaniach wykazano, iż pomimo zapewnienia średniej podaży energii wymaganej dla danej grupy wieku i płci, racje pokarmowe pacjentów obu płci cechował niedobór witaminy D, folianów, potasu, wapnia, a także witamin E i C, magnezu u mężczyzn oraz żelaza i jodu u kobiet. Nadmierną zawartość stwierdzono w przypadku witamin B2, B6, sodu, fosforu w racjach pokarmowych pacjentów obu płci oraz witamin A, B1, niacyny w racjach pokarmowych kobiet, a także witaminy B12 w racjach pokarmowych mężczyzn.WnioskiDowolna suplementacja diety pacjentów ze schizofrenią wydaje się niewskazana, ma ona uzasadnienie tylko w indywidualnych przypadkach chorych, u których stwierdzono na podstawie analizy nawyków żywieniowych niedobory w zakresie witamin i składników mineralnych. Niezbędne jest natomiast zapewnienie każdej osobie chorej na schizofrenię odpowiedniej edukacji żywieniowej, która umożliwi im dobór produktów zawierających wszystkie składniki pokarmowe potrzebne do prawidłowego funkcjonowania organizmu, w tym ośrodkowego układu nerwowego.
An improper energy structure and an improper content of nutrients can, in the future, contribute to the development of many somatic diseases, thus leading to deterioration of life quality of subjects and preventing the maintenance of mental health.
Background The aim of this study was to assess the influence of socio-demographic and clinical factors on personality trait expression and their relationship with more intense interdialytic disorders and changes in health behaviors of patients with chronic kidney disease (CKD). Material/Methods A total of 200 participants were recruited for the research (84 women and 116 men; aged 61±12 years): 160 patients had CKD stage G4–G5 and 40 healthy participants constituted a control group. A diagnostic poll method was used in the research employing the following questionnaires to collect socio-demographic and clinical data: Health Behavior Inventory (IZZ), Personality Inventory (NEO-FFI), Beck Depression Inventory (BDI), and Researcher’s Questionnaire Test. Results Statistically significant differences were found in the intensity of personal traits at different stages of treatment. The influence of factors resulting from CKD on the expression of personality traits increased with subsequent stages of treatment. Depression intensity was not connected with the expression of personality traits. A higher frequency of reported interdialytic disorders was significantly related to a higher degree of openness and conscientiousness and a lower degree of agreeableness. Increased extraversion, conscientiousness, and openness were significantly correlated with more intense health behaviors. Conclusions Personalities of patients with CKD changed with subsequent stages of treatment and were influenced by socio-demographic and clinical factors. Personalities affected the frequency of reported interdialytic disorders and health behaviors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.